ISR Immune System Regulation Holding AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ISR.ST research report →
Companyisrab.se
ISR Immune System Regulation Holding AB (publ) researches and develops drugs for the treatment of viral infections in Sweden. The company's product pipeline includes Covid-19 vaccine, HBV, HIV, and oncology. The company is headquartered in Stockholm, Sweden.
- CEO
- Ola S. Winqvist
- IPO
- 2017
- Employees
- 5
- HQ
- Stockholm, SE
Price Chart
Valuation
- Market Cap
- $96.61M
- P/E
- -1.23
- P/S
- 0.00
- P/B
- 2.51
- EV/EBITDA
- -0.55
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -211.70%
- ROIC
- -198.76%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-78,621,000 · -143.82%
- EPS
- $-1.14 · -86.89%
- Op Income
- $-78,609,000
- FCF YoY
- -33.55%
Performance & Tape
- 52W High
- $9.25
- 52W Low
- $1.19
- 50D MA
- $2.48
- 200D MA
- $5.03
- Beta
- 0.44
- Avg Volume
- 250.75K
Get TickerSpark's AI analysis on ISR.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ISR.ST Coverage
We haven't published any research on ISR.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ISR.ST Report →